Hypothesis

TERT's non‑canonical mitochondrial localization protects the organelle from oxidative damage, thereby reducing the production of reactive oxygen species that drive both telomere attrition and epigenetic drift. We propose that enhancing this mitochondrial shield—without extending telomeric repeats—will lower epigenetic age as measured by Causage/DamAge/AdaptAge clocks while leaving cancer risk unchanged or decreased.

Mechanistic Basis

• Telomere shortening primarily reflects the end‑replication problem, but oxidative stress accelerates loss beyond the replication counter 1.
• TERT can translocate to mitochondria where it scavenges ROS, stabilizes membrane potential and limits mtDNA damage 2, 3.
• Mitochondrial ROS influence nuclear DNA methylation patterns, contributing to epigenetic aging signatures 5.
• Therefore, TERT's mitochondrial activity links telomere biology to epigenetic clocks through a shared oxidative stress pathway.

Testable Predictions

1. Prediction 1: Forced mitochondrial targeting of TERT (e.g., adding a mitochondrial localization signal) in human fibroblasts will decrease mitochondrial ROS production by ≥30% and lower mtDNA 8‑oxoguanine levels, without altering average telomere length after 30 population doublings.
2. Prediction 2: The same intervention will reduce the rate of epigenetic aging, measured as a slower increase in CausAge/DamAge scores per passage, compared to control cells expressing cytosolic TERT or empty vector.
3. Prediction 3: Cells with mitochondrial‑targeted TERT will not show increased soft‑agar colony formation or xenograft tumorigenicity relative to controls, indicating that the oncogenic risk associated with TERT overexpression is not heightened when its telomere‑synthetic activity is uncoupled from its mitochondrial protective function.
4. Prediction 4: Pharmacological inhibition of TERT's mitochondrial import (using a peptide blocker) will accelerate epigenetic aging and increase sensitivity to oxidative stress, even when telomerase activity is chemically inhibited.

Experimental Approach

• Generate lentiviral vectors expressing (a) wild‑type TERT, (b) TERT fused to a strong mitochondrial targeting sequence (MTS‑TERT), and (c) a catalytically dead TERT mutant (DN‑TERT) as a negative control.
• Transduce human diploid fibroblasts (e.g., IMR‑90) and select stable lines.
• Measure: mitochondrial ROS (MitoSOX), mtDNA lesion frequency (qPCR‑based lesion assay), telomere length (TRF or qPCR), and epigenetic clocks (CausAge, DamAge, AdaptAge) at passages 0, 10, 20, 30.
• Assess tumorigenic potential via soft‑agar assay and subcutaneous injection into immunocompromised mice.
• Include a rescue experiment where MTS‑TERT cells are treated with a mitochondria‑targeted antioxidant (MitoQ) to verify phenotype specificity.

Potential Implications

If validated, this hypothesis would re‑frame TERT as a modular regulator: its telomere‑synthetic domain can be therapeutically separated from its mitochondrial antioxidant domain. Strategies that boost mitochondrial TERT—such as small‑molecule promoters of TERT import or mitochondria‑targeted TERT mRNA—could delay epigenetic aging without raising cancer incidence, offering a safer alternative to global reprogramming or telomerase activation.

All experiments are falsifiable; failure to observe the predicted ROS reduction, epigenetic clock modulation, or unchanged tumorigenicity would refute the core claim.